Stockscreener 앱 받기
13.63
0.51%
-0.07
전일 마감가:
$13.70
열려 있는:
$13.7
하루 거래량:
201.54K
Relative Volume:
0.30
시가총액:
$823.09M
수익:
-
순이익/손실:
$-117.99M
주가수익비율:
-6.3701
EPS:
-2.1397
순현금흐름:
$-79.92M
1주 성능:
-3.47%
1개월 성능:
+24.25%
6개월 성능:
-40.92%
1년 성능:
-25.92%
1일 변동 폭
$13.27
$13.79
1주일 범위
$12.92
$14.35
52주 변동 폭
$10.52
$34.48
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
13.63 | 823.09M | 0 | -117.99M | -79.92M | -2.1397 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | JP Morgan | Overweight |
| 2025-08-27 | 개시 | Needham | Buy |
| 2023-12-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-10-05 | 개시 | Stifel | Buy |
| 2023-06-14 | 개시 | BofA Securities | Buy |
| 2023-06-12 | 개시 | H.C. Wainwright | Buy |
| 2023-06-08 | 개시 | Robert W. Baird | Outperform |
| 2023-05-10 | 개시 | Pareto | Buy |
| 2023-04-28 | 개시 | Wedbush | Outperform |
모두보기
Oculis Holding Ag 주식(OCS)의 최신 뉴스
Technical Reactions to OCS Trends in Macro Strategies - Stock Traders Daily
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Price to book forward of Oculis Holding AG – SWB:CR5 - TradingView
Price to earnings forward of Oculis Holding AG – NASDAQ:OCS - TradingView
Price to sales forward of Oculis Holding AG – NASDAQ:OCS - TradingView
Enterprise value to revenue forward of Oculis Holding AG – SWB:CR5 - TradingView
Oculis Holding AG Warrants 2023-06.03.28 on OCULIS HOLDING Financial Disclosures & SEC Filings - TradingView
Oculis stock gains after FDA trial design agreement - Investing.com
Oculis to present updates on late-stage eye dis... - Pluang
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - The Manila Times
Oculis to Participate in Piper Sandler Virtual Ophthalmology Conference Fireside Chat - Quiver Quantitative
Oculis spotlights late-stage eye drugs at Piper Sandler event - Stock Titan
Trading the Move, Not the Narrative: (OCS) Edition - Stock Traders Daily
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway - TipRanks
Oculis Holding AG Actuals & Estimates (NASDAQ:OCS) - TradingView
Oculis Holding AG Warrants (OCSAW) See Upward Momentum Amid Modest GainsSign of Strength - dars.gov.et
Oculis (NASDAQ: OCS) details late-stage eye drugs and cash runway into 2029 - Stock Titan
OCS Forecast — Price Target — Prediction for 2027 - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AGOCS - PR Newswire
OCSOculis Holding AG Revenue Breakdown - Finviz
Oculis Holding AG (OCSAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oculis Holding AG (OCS) Edges Lower Amidst Sector Headwinds; Support Levels in FocusUpthrust Pattern - dars.gov.et
(OCS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Oculis Holding AG (OCS) Institutional Confidence - TradingKey
Oculis Holding AG (OCS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oculis Holding AG (OCS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oculis Holding AG (OCS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oculis Holding AG (OCS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OCS News | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
Oculis Holding AG (OCS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oculis Holding AG (OCS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oculis Holding AG (OCS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oculis Holding AG (OCSAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oculis Holding AG (OCSAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oculis Holding AG (OCSAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oculis Holding AG (OCSAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oculis Holding AG (OCSAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oculis Holding AG (OCSAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oculis Holding AG (OCSAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oculis Holding AG (OCSAW) Institutional Confidence - TradingKey
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm - GlobeNewswire
Oculis : Minutes of the 2026 Annual General Meeting of Shareholders - marketscreener.com
Investors sue Oculis Holding AG over failed dru... - Pluang
Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment - Streetwise Reports
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles - AOL.com
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Oculis shelves FDA filing after phase 3 DME trials miss key vision goals - MSN
Oculis enrolls first patient in licaminlimab PREDICT-1 DED trial - Optometry Times
Oculis Holding Ag (OCS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):